Myelofibrosis: facing the future by challenging the past

Myelofibrosis (MF) is experiencing a lively moment from a scientific point of view. As hypothesized in previous editions of the meeting, JAK2 inhibitors retain a backbone role in newer and promising therapeutic combinations that could undermine the pathogenic basis of MF. Biological data collected in clinical trials highlight the possibility of modulating some important features that drive disease aggressiveness, such as fibrosis, allelic burden of mutations, proinflammatory cytokines, and the microenvironment. The result is an overall improvement in clinical outcomes, which the scientific community is watching with increasing interest. This year’s congress aims to devise the best strategies for MF patients starting from their preclinical rationale.